Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
GANX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Gain Therapeutics, Inc.NASDAQ: GANX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.76M rose 22.4% year over year, ahead of the +1.7% change in trailing-twelve-month research & development. Sequentially, it rose 17.7% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +22.4% holds above the trailing-twelve-month pace of +1.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 10.21M USD
- Year-over-year change
- -5.4%
- 4-year CAGR
- +9.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.21M | -5.4% |
| FY2024 | 2024-12-31 | 10.79M | -6.3% |
| FY2023 | 2023-12-31 | 11.52M | +37.5% |
| FY2022 | 2022-12-31 | 8.38M | +16.9% |
| FY2021 | 2021-12-31 | 7.16M | — |
Research & Development vs competitors
How GANX compares with its peers on the latest reported figures
- GANX's LTM Mar 2026 research & development of $10.72M is the 6th highest of the 9 companies compared; the peer median is $35.53M.
- Its year-over-year change of +1.7% is the 3rd highest of 8, against a peer median of -5.4%.
- Over three fiscal years its annual growth of +6.8% compares with a peer median of +13.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $93.8M | -4.5% | +11.6% | — | |
| LTM Mar 2026 | $40.98M | +3.6% | +14.5% | — | |
| LTM Jun 2024 | $30.07M | — | -35.3% | 3686.7% | |
| LTM Mar 2026 | $10.72M | +1.7% | +6.8% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Apr 2026 | $1.45M | -48.6% | +24.4% | 80.7% | |
| Peer median (excluding GANX) | $35.53M | -5.4% | +13.1% | 186.8% | |
Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 164.99K | 140.11K | 55.18K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 164.99K | 140.11K | 55.18K | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 7.16M | 8.38M | 11.52M | 10.79M | 10.21M |
| Selling, General & Admin | 6.83M | 9.54M | 10.79M | 9.56M | 8.5M |
| Operating Expenses | 13.99M | 17.92M | 22.31M | 20.35M | 18.71M |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| EBITDA | (13.87M) | (17.43M) | (22.1M) | (19.79M) | (19.21M) |
| EBITDA Margin | -8407.0% | -12443.0% | -40059.2% | — | — |
| Operating Income | (13.83M) | (17.78M) | (22.25M) | (20.35M) | (18.71M) |
| Operating Margin | -8379.8% | -12688.1% | -40328.3% | — | — |
| Interest Income | 12.5K | 375.36K | 494.23K | 357.1K | 244.39K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (60.43K) | 279.28K | 64.89K | 476.22K | (589.28K) |
| Income Before Tax | (13.89M) | (17.5M) | (22.19M) | (19.87M) | (19.3M) |
| Pre-Tax Margin | -8416.4% | -12488.8% | -40210.7% | — | — |
| Income Tax Expense | 4.01K | 92.98K | 79.28K | 536.82K | 861.12K |
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Net Margin | -8418.9% | -12555.1% | -40354.3% | — | — |
| EPS (Basic) | (1.37) | (1.48) | (1.71) | (0.89) | (0.61) |
| EPS (Diluted) | (1.37) | (1.48) | (1.71) | (0.89) | (0.61) |
| Weighted Avg Shares | 10.17M | 11.88M | 13.01M | 22.88M | 32.97M |
| Weighted Avg Shares (Diluted) | 10.17M | 11.88M | 13.01M | 22.88M | 32.97M |
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.